Solar stocks drop sharply as Senate Republicans detail changes to Trump’s tax-and-spending bill that would phase out solar, ...

The pending deal was rumored overnight after a report from the Financial Times, spurring analysts to speculate that if true, ...

US Big Pharma firm Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion as the ...

Global stock markets face uncertainty as Israel-Iran conflict impacts investor confidence, causing shifts in energy stocks ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to US$1.3 billion to boost its pipeline beyond its blockbuster weight-loss and diabetes drugs.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

In today's Pharmalittle roundup, we're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more.

Yum Brands named Chief Financial Officer Chris Turner as its next chief executive. Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion Deal would add a potential treatment for ...

Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing therapies targeting genes that regulate cholesterol in the liver.

Iran and Israel's air war, which began on Friday when Israel attacked Iran's nuclear facilities, has raised concerns that the ...

Surgery Partners rejects Bain Capital's acquisition bid, citing greater long-term value as a public company with strong ...